Non-small cell lung cancer (NSCLC) represents 75-80% of all lung carcinomas, which is the most common cause of death from cancer. Tumour suppressor candidate 3 (TUSC3) is pivotal in many biochemical functions and cytological processes. Dis-regulation of TUSC3 is frequently observed in epithelial cancers. In this study, we observed up-regulated TUSC3 expression at the mRNA and protein levels in clinical NSCLC samples compared with adjacent non-tumorous lung tissues. The expression level of TUSC3 is significantly correlated with tumour metastasis and patient survival. Overexpression of TUSC3 in NSCLC cells led to increased proliferation, migration, and invasion in vitro and accelerated xenograft tumour growth in vivo, while the opposite effects were achieved in TUSC3-silenced cells. Increased GLI1, SMO, PTCH1, and PTCH2 abundance were observed in TUSC3 overexpressed cells using western blotting. Co-immunoprecipitation and immunofluorescence analyses further revealed interaction between TUSC3 and GLI1. In conclusion, our study demonstrated an oncogenic role of TUSC3 in NSCLC and showed that dis-regulation of TUSC3 may affect tumour cell invasion and migration through possible involvement in the Hedgehog (Hh) signalling pathway.
Introduction
Lung cancer accounts for 12% of all new cancers worldwide [1] and is the most common cause of death from cancer [2] . Non-small cell lung cancer (NSCLC) represents 75-80% of all lung carcinomas and has a 5-year survival rate of about 15% [3] . Although the development of chemotherapy and radiation therapy combined with surgery have shown benefits for patient survival [4] [5] [6] [7] [8] , a significant fraction of early-stage NSCLC patients develops distant metastases which are difficult to predict and have greatly affected the overall prognosis [9] . In recent years, several prognostic markers, such as CYFRA 21-1, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), carbohydrate antigen (CA) 125, and CA 19-9 have been identified in NSCLC [10] . However, the reliability and accuracy of using these markers to predict metastasis development and patients' responses to different chemotherapy regimens have remained to be tested [10] . The development of novel and effective therapeutic approaches is based on a better understanding of the molecular and cellular biology of NSCLC.
The TUSC3 gene, located on the chromosomal band 8p22, was originally identified as a potential tumour suppressor in prostate cancer [11, 12] . The molecular function of TUSC3 was inferred from its sequence homology to the yeast protein Ost3p, which forms a subunit of the oligosaccharyltransferase (OST) complex that is responsible for post-and co-translational N-glycosylation of proteins in the endoplasmic reticulum (ER) [13] . Meanwhile, TUSC3 protein is found to be pivotal in many biochemical functions and cytological processes including plasma membrane transport of Mg 2 + [14] [15] [16] . According to the ONCOMINE database, expression of TUSC3 gene is significantly down-regulated in 29 cases but is up-regulated in another 37 cases of clinical cancer (p < 0.05, www.oncomine.org; Fig. S1 ). Among these, two up-regulated cases were reported in lung cancer (Figs. S1, S2). It has been proposed that the facilitation of TUSC3-related carcinogenesis may depend on a certain genetic background and biological circumstance [17, 18] . In A549 lung adenocarcinoma cells, silencing of TUSC3 was found to inhibit growth and proliferation, enhance apoptosis and radiation sensitivity [19] . However, the currently limited evidence of TUSC3 in lung cancer was obtained from a single cell line or large-scale gene expression profiling using microarray experiments [19] [20] [21] . The role of TUSC3 in carcinogenesis of NSCLC has not been characterized comprehensively so far. The Hedgehog (Hh) signalling pathway was initially identified in Drosophila as a crucial mediator of numerous biological processes during embryogenesis [22] . Inappropriate reactivation of the Hh pathway in adult tissue can lead to development of medulloblastoma, brain tumour, and breast cancer [23] [24] [25] . Studies have also demonstrated that the Hh pathway is involved in regulating the self-renewal of cancer stem cells in myeloma, brain tumour, pancreatic adenocarcinomas, and lung cancer [26] [27] [28] [29] [30] . Inhibition of the Hh signalling pathway blocked the growth of CD133 + cells of NSCLC [31] . In this work we examined the expression level of TUSC3 in clinical NSCLC samples and analysed the correlation between TUSC3 expression and NSCLC progression and prognosis. We also present the first evidence of TUSC3 involvement in the Hedgehog (Hh) signalling pathway and demonstrate the effects of aberrant TUSC3 expression on the cellular biological behaviour of NSCLC cells in vitro as well as tumour growth in vivo.
Materials and methods

Patients and tissue samples
All work involving the use of human subjects was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki; http://www.wma.net/en/30publications/ 10policies/b3/). All protocols were approved by the Committee on the Ethics of Animal Experiments of Southern Medical University. For the use of clinical materials, written informed consent forms for the scientific use of biologic material were signed by all participating patients according to the requirements of the ethical protocols of Nanfang Hospital, Southern Medical University (Guangzhou, China). 67 samples of NSCLC tumour tissue and the matched adjacent normal tissue taken from the same patient were collected from September 2009 to September 2010 at the Department of Pathology, Southern Medical University (Guangzhou, China). None of the patients had received radiotherapy or chemotherapy before surgery. The medical records of the patients were reviewed and the clinicopathologic features were collected. The clinical stage of NSCLC was evaluated according to the TNM, LNM (lymph node metastasis), and DM (distant metastasis) classification systems. Pathological staging was performed according to the criteria of the American Joint Committee on Cancer by 3 pathologists independently in a double-blinded manner.
All the tissue biopsies were freshly frozen in liquid nitrogen (or fixed in 10% formalin) within 1 h after surgical resection. Samples for quantitative real-time PCR (qRT-PCR) and western blotting analyses were stored at −80°C. Samples for the immunohistochemical assay were embedded in paraffin and sectioned consecutively at 4 μm thickness using a rotary microtome.
Cell culture and lentiviral transduction
The human NSCLC cell lines (H460, A549, SPC-A1, PC-9, H1299, GLC-82, and H322) and the human bronchial epithelial cell (16HBE) were originally purchased from the American Type Culture Collection (Manassas, VA). All cell lines were authenticated by DNA short tandem repeat (STR) profiling before distribution. Cells were cultivated in RPMI-1640 medium enriched with 10% heat-inactivated fetal bovine serum (FBS) at 37°C in a humidified atmosphere with 5% CO 2 .
Overexpression and down-regulation of TUSC3 were performed by lentiviral delivery using the pEZ-Lv105 vector and the psi-LVRH1GP shRNA lentiviral vector (GeneCopoeia, CA) containing TUSC3 shRNA and HEK293T packaging cell line. TUSC3 overexpressed H322 cell lines, TUSC3 silenced A549 cell lines, and TUSC3 overexpressed A549 cell lines were constructed. Cells transduced with empty lentiviral vectors were used as negative controls of TUSC3-overexpressed cells. Cells transduced with scrambled shRNA were used as negative controls of TUSC3-silenced cells. Recombinant lentiviruses were produced by transient transfection in 293T cells using the calcium phosphate method. Transduced cells were selected in medium containing puromycin (3 μg/ml). Protein and mRNA samples were taken for western blotting and qRT-PCR analyses.
Immunohistochemical assay
The sections were deparaffinised and rehydrated, and endogenous peroxidase was inhibited with 0.3% H 2 O 2 methanol. For antigen retrieval, slides were boiled in 0.01 M, pH 6.0 sodium citrate buffer for 15 min in a microwave oven. After blocking with the 5% normal goat serum, primary antibody (rabbit anti-TUSC3, Sigma Aldrich, MO) in blocking buffer (1:50 dilution) was applied and the slides were incubated at 4°C overnight. The sections, after 2 × PBS washes, were treated with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (1: 2000, #7074, Cell Signalling, Danvers, MA). Finally, the visualization signal was developed with 3-3′-diaminobenzidine-hydrogen peroxide (Maixin, Fuzhou, China), and the slides were counterstained in haematoxylin.
The total TUSC3 immunostaining score was calculated as the sum of the percentage positivity of stained tumour cells and the staining intensity. The positive percentage was scored from 0 to 3, with 0 for < 10%, 1 for 10%-30%, 2 for 30%-50%, and 3 for > 50%. The staining intensity was scored from 0 to 3, with 0 for no staining, 1 for weakly stained, 2 for moderately stained, and 3 for strongly stained. Then the score of TUSC3 expression was calculated with the value of the positive percentage score × staining intensity score, which ranged from 0 to 9. The final expression level of TUSC3 was defined as "low" (0-4) and "high" (5-9).
Quantitative real-time PCR
Total RNA was extracted using the Trizol reagent (Invitrogen, CA) according to the manufacturer's instructions. RNA quantity and quality were checked using NanoDrop (ND-2000c, Thermo Scientific) and a 1% agarose gel. Approximately 1 μg of each obtained RNA sample was used as the template for first-strand cDNA synthesis using a RevertAid™ First Strand cDNA Synthesis Kit (Fermentas, Ontario, Canada). Quantitative real-time PCR was carried out on an ABI StepOne Plus Real-Time PCR System (Applied Biosystems, CA) using the Platinum SYBR green master mix (Invitrogen, CA). Amplification was performed in 20 μl reactions containing 10 μl of 2 × Master Mix, 0.3 μl of each primer (10 μM) and 0.5 μg of template cDNA. Sequences of all primers are provided in Table  S1 . Each experiment was conducted with at least three independent replicates. Transcription of the house-keeping gene, ACTIN, was quantified as an internal control. Relative quantification of mRNA expression was calculated using the ΔΔCt method.
Immunoblotting and co-immunoprecipitation
NSCLC cells were lysed on ice in radio immunoprecipitation assay (RIPA) buffer. Protein lysates were resolved on 10% SDS polyacrylamide gel, transferred onto PVDF (polyvinylidene fluoride) membranes (Immobilon P; Millipore, MA), and blotted according to standard methods using the following antibodies: E-cadherin (1:500, #SAB55022, Sigma Aldrich); vimentin (1:500, #V6630, Sigma Aldrich); β-actin (1:5000, #a5441, Sigma Aldrich); TUSC3 (1:500, #SAB4503183, Sigma Aldrich); β-catenin (1:500, #C2206, Sigma Aldrich); GLI1 (1:500, #3538, Cell Signalling, MA); SMO (1:500, ab72130, Abcam, MA); PTCH1 (1:500, #2428, Cell Signalling, MA); and PTCH2 (1:500, #2464, Cell Signalling, MA). Finally, the respective HRP-conjugated secondary antibodies were applied and signals were detected by enhanced chemiluminescence (Pierce, IL).
For co-immunoprecipitation, NSCLC cell lysates were prepared as described above from NSCLC cell line H322. The cell lysates were cleared by centrifugation at 15,000 rpm for 10 min at 4°C, followed by incubation with pre-blocked Protein A Sepharose beads (Zymed). Precleared lysates were incubated overnight at 4°C with the respective antibodies (TUSC3, 1:500, #SAB4503183, Sigma Aldrich; GLI1, 1:500, #3538, Cell Signalling; normal rabbit IgG, #A0545, Sigma Aldrich) and precipitated with protein A Sepharose (GE Healthcare). Beads were washed three times in lysis buffer and bound proteins were separated with SDS/PAGE and visualized by western blotting.
MTT assay
Cells were seeded in 96-well plates at a density of 1 × 10 3 per well and shaken on a microplate shaker for 1 to 7 days. On each day, 20 μl of 5 g/l 3-(4,5-dimethylthiazol-z-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma Aldrich, MO) was added to each well. To observe the effects of Hh signalling in cellular behaviour and examine the correlation between TUSC3 expression and Hh signalling, we also set up the Hh-activated group and the Hh-inhibited group in TUSC3 silenced cells and TUSC3 overexpressed cells, respectively. The Hh-activated group was treated with 1 nM of HH-Ag1.5, which is an agonist of the SMO receptor that activates sonic Hh signalling, while the Hh-inhibited group was treated with 40 μM of GANT61, which is a small molecule binding to the GLI1 protein. After 4 h incubation at 37°C, the medium was discarded and 150 μl of dimethyl sulfoxide (DMSO) (Sigma Aldrich, MO) was added. The absorbance was measured using a Microplate Autoreader (Bio-Rad, CA) at 490 nm. The experiment was performed with three replicates.
Colony formation assay
Cells were seeded in 6-well plates at a density of 2 × 10 2 per well and incubated at 37°C in a humidified atmosphere with 5% CO 2 . After two weeks, cells were fixed and stained with haematoxylin. The number of colonies containing ≥ 50 cells was counted under a microscope. The experiment was performed with three replicates for each cell line.
Wound healing assay
Cells infected with TUSC3 overexpressed or silenced recombinant lentiviruses were seeded in 6-well plates at a density of 1.25 × 10 6 per well for 24 h to 80-90% confluence. Then the cells were serum starved and cultured in PBS free medium for 24 h. 1 nM of HH-Ag1.5 was added into the medium of the Hh-activated group and 40 μM of GANT61 was added into the medium of the Hh-inhibited group. Wounds were created in lines across each well using a 10 μl standard pipette tip and cell debris was removed using 2 × PBS washes. At this time point (t = 0), wound margins were photographed at various times as indicated in the figure legends and migration was monitored for up to 24-48 h. Images were captured using an image-analysing framegrabber card (LG-3 Scientific Frame Grabber; Scion, MD) and analysed with an image analysis software (NIH Image 1.55). Cell motility was quantified by measuring the distance between the front edges of invasive cells in three randomly selected microscopic fields (×200) at each time point. The experiment was performed with three replicates.
Migration assay
Cells infected with TUSC3 overexpressed or silenced recombinant lentiviruses were serum starved for 24 h, then about 5 × 10 4 cells were plated into the upper chamber of 8-μm-pore transwells (Costar, Corning) and 300 μl of 10% FBS in free medium (Gibco, Invitrogen Carlsbad, CA) was added to the lower compartment. 1 nM of HH-Ag1.5 was added into the medium of the Hh-activated group and 40 μM of GANT61 was added into the medium of the Hh-inhibited group. After migration for 24 h, the cells inside the chamber were removed with cotton swabs. The cells in the lower compartment were fixed in 1% paraformaldehyde, stained with haematoxylin and counted in five randomly chosen fields (× 200) under a microscope. Cell counts are expressed as the mean number of cells per field of view. The experiment was performed with three replicates.
Mouse xenograft experiments
The study was carried out strictly according to the ARRIVE guidelines [32] , the National Institutes of Health (NIH) Guidelines for Laboratory Animal Care [33] , and Guidelines for the welfare and use of animals in cancer research [34] . Twenty-four 4-week-old Balb/C athymic nude mice (nu/nu) were obtained from the Animal Centre of Southern Medical University (Guangzhou, Guangdong, China). All mice were maintained under specific pathogen-free conditions and used in accordance with institutional guidelines and approved by the Use Committee for Animal Care. Xenograft tumours were generated by subcutaneous injection of 1 × 10 6 cells from transfected NSCLC cell lines and the control groups (H322/Vector and H322/TUSC3, n = 6; A549/Scramble and A549/shTUSC3, n = 6). The mice were kept under routine laboratory conditions (21-22°C, relative humidity 60% and a 12 h light-dark cycle). The condition of the mice and growth of the resultant primary tumours were monitored every day afterwards. Tumour volume was measured in two perpendicular axes using a calliper and body weight was recorded twice to three times weekly. Tumour volume was calculated using the equation volume = 1/2 (length × width 2 ). All mice were euthanized using CO 2 inhalation according to animal care guidelines. To minimize suffering, animals were sacrificed when tumour size exceeded 1 cm 3 or after 8 weeks, whichever occurred first. The resulting primary tumours were surgically removed, fixed, and sectioned at 4 μm thickness. The sections were observed under a microscope after haematoxylin and eosin (HE) staining.
Immunofluorescence analysis
Cells were seeded on coverslips at a density of 5 × 10 4 per well for 48 h and then probed with primary antibodies against TUSC3 (#SAB4503183, Sigma Aldrich, MO), GLI1 (#3538, Cell Signalling, MA), and SMO (#ab72130, Abcam, MA). The coverslips were then incubated with rhodamine-conjugated or fluorescein isothiocyanate (FITC)-conjugated goat antibodies against rabbit or mouse IgG (antirabbit IgG, #ab6940, Abcam, MA; anti-mouse IgG, #ab97035, Abcam, MA). After counterstaining with 4′,6-diamidino-2-phenylindole (DAPI, Sigma, MO), images were taken using an Olympus FV1000 confocal laser-scanning microscope (Olympus America Inc., NY).
Statistical analysis
All statistical analyses were performed using SPSS 19.0 for Windows (SPSS Inc., Chicago, IL). A two-tailed paired Student's t-test was used to compare the difference between two groups. The χ 2 test was used to analyse the relationship between TUSC3 expression and the clinicopathological features of NSCLC. One way ANOVA and χ 2 tests were used to compare the TUSC3 expression level, cell proliferation ability, and migration rate between different cell groups. Survival curves were plotted by the Kaplan-Meier method and compared with the log-rank test. p < 0.05 was considered statistically significant.
Results
Up-regulation of TUSC3 correlates with aggressive characteristics of NSCLC
Expression of TUSC3 protein in 67 surgical specimens and the paired normal tissues taken from NSCLC patients was determined using the immunohistochemical assay (Fig. 1) . The immunoreactive rates of TUSC3 were detected at variable levels and localized in the cellular cytoplasm (Fig. 1) . The results revealed high expression of TUSC3 in 80.6% (54/67) of the NSCLC tissue samples and low expression of TUSC3 in 19.4% (13/67) of the NSCLC tissue samples (Table 1) . By contrast, in the paired normal lung samples, TUSC3 expression was undetectable in 37 (55.2%) cases (staining score 0; present positivity score 0) and weakly detected in 30 (44.8%) cases (staining score 1; present positivity score 0 to 1). The TUSC3 immunoreactivity scores showed that high expression of TUSC3 was positively associated with the LNM stage (lymph node metastasis) and tumour differentiation (p < 0.05; Table 1 ). However, no statistically significant relationship was detected between TUSC3 expression and the TNM stage, the DM (distance metastasis) stage, and other clinicopathological parameters including age, gender, and tumour histology ( Table 1) .
Results of qRT-PCR showed that the relative expression levels of TUSC3 were significantly higher in the surgical NSCLC tissues than in the paired normal tissues (T/N > two fold, p < 0.05; Fig. 2A) . Furthermore, the expression of TUSC3 increased along with the progression of T classifications (Fig. 2B), N classifications (Fig. 2C ), M classifications (Fig. 2D) , lymph node metastasis (p < 0.05; Fig. 2E ), and tumour differentiation (p < 0.05; Fig. 2F ). The median relative expression level (3.86) of TUSC3 in all 67 NSCLC samples was chosen as the cut-off point for separating tumours with low expression (< median, n = 34) and high expression (≥ median, n = 33). Kaplan-Meier survival analysis and log-rank tests revealed that patients with high TUSC3 expression had shorter survival times, whereas those with low TUSC3 expression had longer survival times (log-rank p = 0.001; Fig. 2G ). PC-9, H1299, GLC-82, and H322, as well as the human bronchial epithelial cell line, 16HBE. All the seven NSCLC cell lines showed higher expression level of TUSC3 mRNA compared with the human bronchial epithelial cell line (Fig. 3A) . Among the seven cell lines, TUSC3 expression was the highest in the A549 cells and the lowest in the H322 cells (Fig. 3A) . Further analysis of western blotting revealed varying levels of TUSC3 expression in all the NSCLC cell lines. However, TUSC3 expression in the normal epithelial cell line was hardly detected (Fig. 3B) .
To evaluate the possible role of TUSC3 in NSCLC pathogenesis, we overexpressed TUSC3 in H322 cells using lentiviral transduction. TUSC3 expression in H322-TUSC3 cells was significantly increased compared with the expression levels in control cells at both the mRNA and the protein levels (p < 0.05; Figs. 4A, 7A). MTT and colonyformation assays demonstrated that overexpression of TUSC3 in NSCLC significantly increased the growth rate of H322-TUSC3 cells compared with the control cells (p < 0.05; Fig. 4B, C) . Additionally, overexpression of TUSC3 provokes significantly higher migration rate and more rapid wound closure in H322-TUSC3 cells as revealed by the transwell migration assay and wound healing assay (p < 0.05; Fig. 4D, E) . We next investigated the role of TUSC3 in tumourigenesis in vivo. We performed tumourigenesis assays in nude mice by subcutaneous injection of H322-TUSC3 cells and control cells. Palpable tumours were detected on day 10 after injection. Tumours from the H322-TUSC3 group grew much faster and were significantly larger than those from the control group (p < 0.05) at day 42 with average sizes of 4261.750 mm 3 and 2232.917 mm 3 , respectively (Fig. 4F, G) . The expression of TUSC3 in the tumours was measured by qRT-PCR, which indicated a significantly higher expression level of TUSC3 in the H322-TUSC3 group than the control group (p < 0.05; Fig. 4I ). Haematoxylin-eosin (HE) staining revealed that the histopathological features of the developed tumour tissues resembled human NSCLC cancer (Fig. 4H) . Our results indicated that overexpression of TUSC3 can increase the proliferation, migratory, and invasive capacities of NSCLC cells in vitro and promote tumour growth in vivo.
Inhibition of endogenous TUSC3 represses cell proliferation, migration, and tumour growth ability of human NSCLC cells
Next, we suppressed TUSC3 in NSCLC cells A549 using a lentiviral vector carrying a specific TUSC3 shRNA. A considerable reduction of TUSC3 expression was achieved at both the mRNA and the protein levels (Figs. 5A, 7A) . Suppression of TUSC3 significantly decreased the growth rate and inhibited cell proliferation (p < 0.05; Fig. 5B, C) of A549-shRNA-TUSC3 cells compared with that of A549-scramble cells. The migratory and invasive abilities were also significantly lower in A549-shRNA-TUSC3 cells than A549-scramble cells (p < 0.05; Fig. 5D,  E) .
Consistently, the in vivo tumourigenesis assay showed that tumours formed in the A549-shRNA-TUSC3 cells grow slower than tumours generated from the control cells (Fig. 5F, G, H) . Palpable tumours were detected on day 10 after injection. Tumours from the A549-shRNA-TUSC3 group were significantly smaller (p < 0.05) than those from the control group at day 42 with average sizes of 1723.583 mm 3 compared with 3724.083 mm 3 , respectively (Fig. 5F, G) . Quantitative RT-PCR indicated a significantly lower expression level of TUSC3 in the xenograft tumours from the A549-shRNA-TUSC3 group than those from the control group (p < 0.05; Fig. 5I ). Overall, depletion of endogenous TUSC3 caused a significant decrease in the proliferation, migratory, and invasive capacities of NSCLC cells in vitro and inhibited tumour growth in vivo.
TUSC3 is involved in the Hedgehog (Hh) signalling pathway
We next investigated the possible oncogenic pathways that may involve the function of TUSC3. We treated the A549-shRNA-TUSC3 cells and the A549-TUSC3 cells with HH-Ag1.5 and GANT61, respectively. Treatment of HH-Ag1.5 in TUSC3 silenced cells A549-shRNA-TUSC3 led to increased proliferation, migratory, and invasive abilities comparable to those observed in the control cells (p < 0.05; Fig. 6A , C, E), while treatment of GANT61 in TUSC3 overexpressed cells A549-TUSC3 led to reduced proliferation, migratory, and invasive abilities (p < 0.05; Fig. 6B, D, F) . Next, we examined expression level changes of protein markers of the Hh signalling pathway. Increased protein abundance of GLI1, SMO, PTCH1, and PTCH2 were observed in H322-TUSC3 cells with remarkably up-regulated TUSC3 expression. On the contrary, decreased protein abundance of GLI1, SMO, PTCH1, and PTCH2 were observed in A549-shRNA-TUSC3 cells, as revealed by western blotting and immunofluorescence analyses (Fig. 7) . Treatment of HH-Ag1.5 and GANT61 in A549-shRNA-TUSC3 cells and A549-TUSC3 cells resulted in higher SMO expression and lower GLI1 expression comparable to the control cells, respectively (Fig. 6G, H) . Co-immunoprecipitation analysis revealed protein-protein interaction between TUSC3 and GLI1, indicating that endogenous human TUSC3 was physically associated with GLI1 (Fig. 8A) . Immunofluorescence analysis showed that TUSC3 expression was mainly localized to the cytoplasm while GLI1 expression was localized to both the cytoplasm and the nucleus (Fig. 8B) . Overexpression of TUSC3 in A549 cells led to increased GLI1 expression in the nucleus and decreased GLI1 expression in the cytoplasm as compared with the control cells (Fig. 8C) .
Since our functional analyses showed that TUSC3 promotes NSCLC cell migration and invasion, we also investigated the expression of markers associated with epithelial-mesenchymal transition (EMT). Western blot analyses did not show evident changes in the expression levels of E-cadherin and vimentin (Fig. 7C) . The expression level of β-catenin, which up-regulates the critical EMT-activator ZEB1 [35] , also did not show evident change in TUSC3 overexpressed or silenced cells as compared with the control cells (Fig. 7C) .
Discussion
The process of cancer metastasis consists of linked sequential steps, including invasion, detachment, circulation, adhesion, extravasation and growth in distant organs [36, 37] . The expression of a considerable number of genes has been shown to affect metastatic capacity of cancer cells. These genes may function through participating in intracellular signalling pathways that regulate proliferation and apoptosis or causing changes in cell surface proteins and secreted proteins involved in cell adhesion, cellular migration, and proteolysis [9, 38] . In NSCLC, the mutations or abnormal expression of cancer suppressor genes such as p53 and APC, and oncogenes such as C-myc have been reported to be correlated with malignant phenotype of tumours [39] [40] [41] .
TUSC3 was originally identified as a potential tumour suppressor gene on the chromosomal band 8p22 in prostate cancer. In this chromosomal region, allelic losses are frequently found in a variety of epithelial malignancies [42] . TUSC3 is down-regulated in prostate, ovarian, and breast cancer [17, 43, 44] . Silencing of TUSC3 in prostate and ovarian cancer cells result in increased cell growth, migration, and invasion [17, 45, 46] . However, conflicting expression profiles for TUSC3 have also been documented. For example, in papillary thyroid carcinoma (PTC) patients, expression of TUSC3 is significantly higher in tumour tissues than in the paired normal tissues [47] . Gene expression analyses in a large patient cohort and cellular functional analyses suggested an oncogenic role of TUSC3 in colorectal cancer (CRC) [18] . Furthermore, homozygous deletion of TUSC3 also occurs frequently in patients with non-syndromic intellectual disability, yet neither the patients nor their parents with normal mental development have family history of cancer [48] [49] [50] . The contradictory expression trends of TUSC3 in different tumour tissues may be explained by a number of factors such as a different cancer model and expression system [18] . Recently, it was proposed that the facilitation of TUSC3-related carcinogenesis may depend on a certain genetic background and biological circumstance [17, 18] .
Concurrently, most studies of TUSC3 have focused on prostate and ovarian cancer, whereas the function of TUSC3 in other cancer types has not been well resolved. Here we showed that TUSC3 overexpression increases the proliferation, migration, and invasion properties of NSCLC cells in vitro and promotes tumour growth in vivo, while silencing of TUSC3 expression leads to completely opposite results. This suggests an invasion-promoting effect of TUSC3 during NSCLC progression. Clinically, TUSC3 was up regulated in tumour samples of NSCLC patients. The expression levels of TUSC3 relative to ACTB were 2-8 fold higher in the surgical NSCLC tissues than in the paired normal tissues (p < 0.05; Fig. 2A ). This ratio is higher than that documented in the ONCOMINE database, where TUSC3 expression was greater than 3.021 and 2.991 fold in two cases of lung carcinoid tumour and large cell lung carcinoma versus normal lung tissues (www.oncomine.org) [20, 21] . The difference in the up-regulation folds of TUSC3 may be partly due to the different cohort size. TUSC3 expression at both the protein and mRNA levels was significantly correlated with lymph node metastasis and tumour differentiation ( Fig. 2E, F ; Table 1 ). Furthermore, Kaplan-Meier survival analysis indicated an impact of TUSC3 on NSCLC survival (log-rank p = 0.001; Fig. 2G ). Our findings supported a positive relationship between TUSC3 expression and NSCLC progression. In line with our results, silencing of TUSC3 was found to inhibit growth and proliferation and enhance apoptosis and radiation sensitivity of hypoxic A549 lung adenocarcinoma cells [19] . Interestingly, in this study we found that both the A549 and H460 cell lines known for harbouring KRAS mutation showed higher TUSC3 expression than the other NSCLC cell lines [51] . Meanwhile, KRAS mutations are frequently detected in CRC and sporadic PTC [52, 53] , in which elevated TUSC3 expressions have been documented and an oncogenic role of TUSC3 has been suggested [18, 47] . By contrast, KRAS is not commonly mutated in prostate cancer, breast cancer, and ovarian cancer [54, 55] , in which down-regulation of TUSC3 expression has been reported [17, 43, 44] . Therefore, the function of TUSC3 in carcinogenesis may be associated with context-or tissue-specific molecular profiles, such as the mutational status of the KRAS gene. Further expression analyses of TUSC3 together with different cancer molecular markers in a wider clinical spectrum will help elucidate the detailed molecular mechanism underlying the complicated role of TUSC3 in human cancer.
In advanced NSCLC, activation of the Hh pathway was found to play a critical role in terms of chemoresistance and prognosis [56] . In vitro studies have demonstrated that the Hh pathway inhibitor, GDC-0449, which binds to and inhibits SMO function alters intracellular Ca 2 + homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells [57] . Meanwhile, inhibition of the Hh pathway by vismodegib sensitized the tumour cells to cisplatin treatment [56] . Activation of the Hh pathway is initiated through binding of mammalian ligands to the Hip1, Patched1 (PTCH1), and Patched2 (PTCH2) transmembrane receptors. The ligand binding relieves the inhibition of PTCH receptors on another transmembrane protein, Smoothened (SMO), thereby triggering a cascade that leads to the activation of GLI transcriptional factors [22] . Several inhibitors of the Hh pathway, such as PTCH and Hip1, are also targeted by the GLI transcriptional factors, thus creating a negative feedback loop that restricts the extent of Hh signalling [58] . In this study, we found that treatment of the TUSC3 silenced A549 cells using HH-Ag1.5 resulted in increased cell proliferation, migratory, and invasive properties comparable to those observed in the control cells, while treatment of the TUSC3 overexpressed A549 cells using GANT61 resulted in the opposite effects (p < 0.05; Fig. 6 ). Meanwhile, increased GLI1, SMO, PTCH1, and PTCH2 abundance were observed in TUSC3 overexpressed NSCLC cells (Fig. 7A) . Immunofluorescence localization showed decreased SMO expression in TUSC3 silenced A549 cells as compared with the control cells (Fig. 7B) . Consistently, up-regulation of SMO expression at both the mRNA and the protein levels was found to be associated with activation of the Hh pathway in prostate cancer cells [59] , leukemic stem cells [60] , and pancreatic cancer-associated fibroblasts [61] . It has been suggested that SMO expression may be a focal point of regulation in tissue regeneration and tumourigenesis [59] . Our results suggest possible involvement of TUSC3 in the regulation of the Hh signalling pathway (Figs. 6, 7) .
The Hh signalling pathway is prevalent in clinical NSCLCs and plays an important role in tumour metastasis [62] . In pancreatic cancer, prostate cancer, as well as NSCLC, activation of the Hh signalling pathway has been shown to be associated with higher metastatic potential and pathway manipulation can modulate invasiveness and metastasis [63] [64] [65] . Therefore, the enhancement of migration and invasion of TUSC3 overexpressed NSCLC cells may be due to activation of the Hh signalling pathway. EMT regulation by Hh signalling pathway have been reported in melanoma and pancreatic cancers [66, 67] . Recent studies also demonstrated an essential role of GLI1 in enhancing EMT, which in turn promotes recurrence and metastasis in NSCLC [31, 68] . However, here we did not observe evident changes from noninvasive epithelial cells to a mesenchymal, spindle cell phenotype in TUSC3 over-expressed NSCLC cells, nor did we detect significant changes in the expression levels of EMT markers E-cadherin and vimentin, as well as β-catenin, which up-regulates the critical EMTactivator ZEB1 (Fig. 7C) [35] . This may suggest that either the increase of GLI1 expression level related with TUSC3 overexpression was not strong enough to induce EMT transition, or the EMT transition was not evident enough to be detected. It has been proposed that the increase of metastatic growth of cells with high Hh signalling activity could be due to a growth advantage [69] . Furthermore, a study in ovarian cancer reported that instead of Hh-induced EMT transition, Hh-related activation of FAK signalling mediated by elevated ITGB4 protein expression was responsible for increased motility and invasiveness of ovarian cancer cells [70] . Therefore, it is possible that activated Hh signalling regulates metastasis not only through EMT transition, but also through other signalling pathways in NSCLC. Further studies of more detailed mechanisms leading to increased NSCLC cell aggressiveness mediated by TUSC3 overexpression and Hh signalling activation may provide empirical evidence for this hypothesis.
Previous study has shown that with the absence of Hh signalling, GLI proteins are sequestered in the cytoplasm by a GLI interacting protein, suppressor of fused (Sufu) [71] . Activation of the Hh signalling inhibits the Sufu activity, thus allowing GLI1 and GLI2 to translocate to the nucleus and bind to target genes to activate transcription [72] . However, the regulation of the nuclear import of GLI proteins has remained unclear [73] . In this study, we detected physical interaction between TUSC3 and GLI1 protein using co-immunoprecipitation analysis (Fig. 8A) . Immunofluorescence analysis showed co-expression of TUSC3 and GLI1 in the cytoplasm (Fig. 8B) . Expression of GLI1 protein or mRNA in the cytoplasm has been detected in human breast adenocarcinoma cells [25] , medulloblastoma [74] , and various types of clinical cancer tissues [75] and was proposed to be associated with the cytoskeleton [76] . However, only the nuclear CLI1 protein expression was found to be correlated with cancer development and poor prognosis [25, 74, 75] . Here we also demonstrated that overexpression of TUSC3 in A549 cells leads to increased GLI1 expression in the nucleus and decreased GLI1 expression in the cytoplasm as compared with the control cells (Fig. 8C) . Since expression of TUSC3 in the cytoplasm has been observed in ovarian cancer cells and CRC cells before [18, 45] , it is possible for TUSC3 to interact with GLI1 and participate in the translocation of GLI1 from the cytoplasm to the nucleus. However, the precise role and detailed mechanisms of TUSC3 in the Hh signalling pathway require further investigation.
Taken together, our findings suggest that TUSC3 is up-regulated in NSCLC and is clinically correlated with NSCLC metastasis and patient survival. Changes in the expression level of TUSC3 may affect tumour cell invasion and migration through possible involvement in the Hh signalling pathway. Further studies of the regulatory network involving TUSC3 function are necessary for a better understanding of the molecular mechanisms underlying tumourigenesis and metastases in NSCLC, which may provide new insights into the development of a useful therapeutic approach for targeting malignant NSCLC.
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